Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

Bevacizumab induced reversible thrombocytopenia in a patient with recurrent high-grade glioma: a case report.

Leal T, Robins HI.

Cancer Chemother Pharmacol. 2010 Jan;65(2):399-401. doi: 10.1007/s00280-009-1118-2. Epub 2009 Sep 16.

PMID:
19756604
2.

Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma.

Chamberlain MC, Johnston S.

J Neurooncol. 2009 Feb;91(3):359-67. doi: 10.1007/s11060-008-9722-2. Epub 2008 Oct 25.

PMID:
18953491
3.

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Chamberlain MC.

Neurology. 2009 Feb 24;72(8):772-3; author reply 773-4. doi: 10.1212/01.wnl.0000339387.03225.0a. No abstract available.

PMID:
19237713
4.

Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma.

Chamberlain MC, Johnston S.

Cancer. 2009 Apr 15;115(8):1734-43. doi: 10.1002/cncr.24179.

5.

Bevacizumab does not increase the risk of remote relapse in malignant glioma.

Wick A, Dörner N, Schäfer N, Hofer S, Heiland S, Schemmer D, Platten M, Weller M, Bendszus M, Wick W.

Ann Neurol. 2011 Mar;69(3):586-92. doi: 10.1002/ana.22336.

PMID:
21446027
6.

Salvage therapy with single agent bevacizumab for recurrent glioblastoma.

Chamberlain MC, Johnston SK.

J Neurooncol. 2010 Jan;96(2):259-69. doi: 10.1007/s11060-009-9957-6. Epub 2009 Jul 11.

PMID:
19593660
7.
8.

Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma.

Drappatz J, Lee EQ, Hammond S, Grimm SA, Norden AD, Beroukhim R, Gerard M, Schiff D, Chi AS, Batchelor TT, Doherty LM, Ciampa AS, Lafrankie DC, Ruland S, Snodgrass SM, Raizer JJ, Wen PY.

J Neurooncol. 2012 Mar;107(1):133-8. doi: 10.1007/s11060-011-0717-z. Epub 2011 Oct 8.

PMID:
21984064
9.

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Mrugala MM.

Neurology. 2009 Feb 24;72(8):773; author reply 773-4. No abstract available.

PMID:
19248218
10.

D-dimer elevation and paresis predict thromboembolic events during bevacizumab therapy for recurrent malignant glioma.

Misch M, Czabanka M, Dengler J, Stoffels M, Auf G, Vajkoczy P, Stockhammer F.

Anticancer Res. 2013 May;33(5):2093-8.

PMID:
23645760
11.

Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen.

Parekh C, Jubran R, Erdreich-Epstein A, Panigrahy A, Bluml S, Finlay J, Dhall G.

J Neurooncol. 2011 Jul;103(3):673-80. doi: 10.1007/s11060-010-0444-x. Epub 2010 Nov 1. Erratum in: J Neurooncol. 2011 Jul;103(3):681.

PMID:
21038110
12.

Bevacizumab at recurrence in high-grade glioma.

Salmaggi A, Gaviani P, Botturi A, Lamperti E, Simonetti G, Ferrari D, Silvani A.

Neurol Sci. 2011 Nov;32 Suppl 2:S251-3. doi: 10.1007/s10072-011-0799-6. Review.

PMID:
21987287
13.

Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas.

Hwang EI, Jakacki RI, Fisher MJ, Kilburn LB, Horn M, Vezina G, Rood BR, Packer RJ.

Pediatr Blood Cancer. 2013 May;60(5):776-82. doi: 10.1002/pbc.24297. Epub 2012 Sep 13.

PMID:
22976922
14.

10 Questions about the use of bevacizumab in the management of recurrent malignant gliomas.

Chamberlain MC.

Neurologist. 2010 Jan;16(1):56-60. doi: 10.1097/NRL.0b013e3181c78aa2. No abstract available.

PMID:
20065801
15.

FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.

Cohen MH, Shen YL, Keegan P, Pazdur R.

Oncologist. 2009 Nov;14(11):1131-8. doi: 10.1634/theoncologist.2009-0121. Epub 2009 Nov 6.

16.

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY.

Neurology. 2008 Mar 4;70(10):779-87. doi: 10.1212/01.wnl.0000304121.57857.38.

PMID:
18316689
17.

Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors.

Benesch M, Windelberg M, Sauseng W, Witt V, Fleischhack G, Lackner H, Gadner H, Bode U, Urban C.

Ann Oncol. 2008 Apr;19(4):807-13. Epub 2007 Dec 3.

PMID:
18056650
18.

Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma.

Shapiro LQ, Beal K, Goenka A, Karimi S, Iwamoto FM, Yamada Y, Zhang Z, Lassman AB, Abrey LE, Gutin PH.

Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):636-42. doi: 10.1016/j.ijrobp.2012.05.031. Epub 2012 Jul 3.

PMID:
22765876
19.

Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials.

Hofer S, Elandt K, Greil R, Hottinger AF, Huber U, Lemke D, Marosi C, Ochsenbein A, Pichler J, Roelcke U, Weder P, Zander T, Wick W, Weller M.

Acta Oncol. 2011 Jun;50(5):630-5. doi: 10.3109/0284186X.2011.572913. Epub 2011 Apr 18.

PMID:
21495907
20.

Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas.

Chamberlain MC.

Cancer. 2010 Sep 1;116(17):3988-99. doi: 10.1002/cncr.25256. Review.

Supplemental Content

Support Center